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induced relaxation was not changed significantly. The contractile 
response to Phe significantly increased in arteries that were incubated 
with ET-1, compared with controls. In addition, PARP-1 and PARP 
expressions increased significantly in thoracic aorta rings incubated 
with ET-1. The diminished vasoreactivity in response to ACh and 
Phe as well as ET-1-related changes in expressions of PARP-1 and 
PAR were significantly improved by the concomitant incubation with 
either PEG-SOD plus apocynin, or PJ34.
Conclusion: The results of this study suggest that ET-1 causes a sig-
nificant alteration in vascular reactivity of thoracic artery, and this 
alteration seems to be via oxidative stress in thoracic artery endothe-
lium with subsequent DNA damage and activation of PARP pathway.
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Introduction: Improvement of left ventricular ejection fraction 
(LVEF) in patients with dilated cardiomyopathy (DCM) can be 
observed after a minimum of 6 months of therapy. Many factors 
contribute to the rate of improvement. We proposed to investigate the 
importance of certain clinical variables and treatment particularities 
on the prognostic of patients with DCM.
Patients (or Materials) and Methods: We included in our study 
patients selected retrospectively from the Clinical County Hospital 
database that had been admitted to the hospital between 2010 and 
2012 with the principal diagnosis of DCM, presented a reduced 
LVEF, and had a follow-up within minimum 6 months. We consid-
ered improvement an increase of > 20% the LVEF value at follow-up. 
We then separated our patients into 2 groups based on improvement 
or no improvement of LVEF. Clinical parameters were compared by 
univariable analysis. The purpose was to identify factors that were 
associated with improvement of LVEF.
Results: In the statistical model, sex, etiology of cardiomyopathy, 
disease duration, NYHA class, heart rate at rest, presence of co-
morbidities (high systolic blood pressure, diabetes), serum sodium 
levels, beta-blocker type, and adherence to treatment were signifi-
cantly associated with improvement of ejection fraction.
Conclusion: The variables observed as being associated with 
improvement of LVEF may be used to identify patients who will 
benefit from standard therapy and those who will need more aggres-
sive pharmacologic therapies or implantable devices.
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Introduction: This study was aimed to examine the effect of chronic 
taurine treatment on corpus cavernosum dysfunction in diabetic rats 
and to investigate possible underlying mechanisms.
Patients (or Materials) and Methods: Thirty male rats were ran-
domized to 3 groups of 10 each, including control, diabetic, and 
taurine-treated diabetic. Diabetes was induced in rats by streptozo-
tosin (STZ, single intraperitoneal dose of 50 mg/kg body weight). 
Taurine was administered orally for 12 weeks (1% w/v in drink-
ing water) from the day on which STZ was injected. At the end of 
the 12th week, strips of corpus cavernosum were suspended in an 
organ bath system for functional studies. Nitric oxide (NO)-mediated 
endothelium-dependent and neurogenic corpus cavernosum relaxa-
tion were evaluated by acetylcholine (ACh, 0.1 nM-100 µM) and 
electrical field stimulation (EFS, 30 V, 5 ms, 2–32 Hz), respectively. 
The expressions of endothelial nitric oxide synthase (eNOS), phos-
phorylated eNOS (p-eNOS) (Ser-1177), neuronal nitric oxide syn-
thase (nNOS), NADPH oxidase subunit gp91phox, Rho A, and Rho 
kinase in corpus cavernosum were semi-quantitatively assessed by 
immunohistochemistry.
Results: Induction of diabetes resulted in significant inhibition of 
NO-mediated endothelium-dependent and neurogenic corpus caver-
nosum relaxation. Furthermore, eNOS, p-eNOS, and nNOS expres-
sions decreased significantly in diabetic rats compared with controls, 
while gp91phox, RhoA, and Rho kinase expressions increased signifi-
cantly. The diminished relaxation response to ACh and EFS as well 
as diabetes-related changes in expressions of these proteins in corpus 
cavernosum of diabetic rats were significantly improved by taurine.
Conclusion: Chronic treatment with taurine improves NO-mediated 
relaxations of corpus cavernosum in diabetic rats, probably by inhib-
iting NADPH oxidase/Rho kinase pathways.
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Introduction: Busulfan has documented interindividual phar-
macokinetic variability. Aim of this work is to evaluate acute 
toxicity of parenteral busulfan administered with initial dose 
recommended by producer and to demonstrate the necessity of 
further intensive therapeutic drug monitoring (TDM) to target 
desired exposure.
Patients (or Materials) and Methods: After the provision of an 
informed consent for the procedure per protocol, which has been 
approved by an independent ethical committee, 46 children (male, 
27; median age, 24 months (2 mo–18 years) underwent condition-
ing with parenteral busulfan and other drugs in different combina-
tions for autologous (n = 11) or allogeneic (n = 35) HSCT. Busulfan 
was infused in 42 patients (91%) over 4 days in 16 doses 2 hour 
infusion q6 hourrs with initial dose calculated on body weight (bw; 
< 9 kg 1.0 mg/kg, 9 < 16 kg 1.2 mg/kg, 16–23 kg 1.1 mg/kg, 23 < 34 
kg 0.95 mg/kg, > 34 kg 0.8 mg/kg). In 4 patients (9%), the scheme 
was 4-hour infusion q12 hours for 4 days, starting dose 2 mg/kg bw. 
TDM was performed prospectively online. Samples were collected for 
2-3 days starting 24 hours after initial dose (immediately before, at 
the end, 2 and 4 hours after the end of infusion). Busulfan concentra-
tion was determined by high-performance liquid chromatography. 
Further doses were changed according to calculated AUC (targeted in 
myeloablative range-infusion q6 hours: 5000–7000 ng/m.h, infusion 
q12 hours: 10,000–12,000 ng/mL.h).
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Results: Dose of busulfan was adjusted in 25 patients (54%). 
Through levels 25 to 1244 ng/mL, peak levels 849–4586 ng/mL 
bearing AUC 2225 ng/mL.h–12,818 ng/mL.h were observed. The 
median total dose of infused drug was 17.52 mg/kg (10.7–22.9). 
All patients have engrafted, 33 (94%) patients after allogeneic 
HSCT have reached complete donor chimerism. Acute graft versus 
host disease grade III-IV manifested in 6 (17%), mucositis grade 
III-IV was seen in 28 (61%), and VOD was diagnosed in 8 (17%) 
patients. Defibrotide was administered in 15 patients (therapeuti-
cally in 9, as prophylaxis in 8). Neurotoxicity was documented 
in 2 patients. Relapse occurred in 6 (13 %) patients; 10 (22%) 
patients died, 5 due to toxicity before day 100 after HSTC, 1 child 
15 months after HSCT, 4 due to relapse. 32 children are alive/
well (70%).
Conclusion: Parenteral busulfan was used in full myeloablative dose 
and in combination with other drugs; therefore, toxicity rather than 
underexposure was our main concern. However, clear correlation 
between AUC and toxicity was not observed. Because of interindivid-
ual differences and changes in pharmacokinetics during the busulfan 
course, we strongly recommend intensive TDM.
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Introduction: Angiogenesis inhibitors have remarkably improved the 
outcome of patients with several types of cancer. One of the most 
reported side effects of angiogenesis inhibitors is hypertension. In a 
previous study, we showed that infusion of bevacizumab, an antibody 
directed against vascular endothelial growth factor (VEGF), acutely 
decreased endothelium-dependent vasodilation in healthy volunteers 
(A. Thijs et al Hypertension 2013;Epub ahead of print). Sunitinib, 
an inhibitor of tyrosine kinases including the VEGF-receptor, causes 
cardiovascular side effects similar to bevacizumab. We expected that 
antagonism of the VEGF receptor and subsequent endothelial dys-
function mediates these cardiovascular adverse events of sunitinib. 
Therefore, we hypothesized that sunitinib reduces endothelium-
dependent vasodilation before hypertension.
Patients (or Materials) and Methods: In patients with metastatic 
renal cell carcinoma before and 1 week after start of clinically 
indicated sunitinib (50 mg/d) the endothelium-dependent vasodi-
lator response to intra-arterial acetycholine (ACH, 0.5, 2.0, and 
8.0 µg/dL forearm volume/min) and the endothelium-independent 
vasodilator response to intra-arterial sodium nitroprusside (SNP, 
0.06, 0.2, and 0.6 µg/dL forearm volume/min) were assessed with 
venous occlusion plethysmography. Moreover, blood pressure was 
measured in supine position at the end of each experiment. For 
statistical analyses, the FBF ratio (FBF in experimental arm/FBF in 
control arm) was logarithmically transformed to obtain a Gaussian 
distribution. Results are expressed as percentage response from 
baseline (mean [SEM]).
Results: Ten male patients with a mean age of 55 years (range, 
24–68 years) were included. No significant changes in FBFresponses 
before and after start of sunitinib were observed (Table). Blood 
pressure (MAP) before was 101.9 (3.8) mm Hg and 106.1 (2.6) 
mm Hg after 1 week of treatment (not significant). After 2 weeks 
of treatment, the blood pressure had increased to 115.8 (4.9) mm 
Hg (P < 0.05).
Conclusion: One-week treatment with sunitinib did not specifically 
affect endothelium-dependent vasodilation before the development 
of hypertension.These observations indicate that bevacizumab and 
sunitinib differ with respect to their vascular actions in humans in 
vivo and suggest that other factors contribute to the development of 
hypertension in response to sunitinib rather than endothelial dys-
function.
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Introduction: Pancreatic cancer patients have an overall 5-year sur-
vival of < 5% worldwide, due to both late-stage diagnosis and lack of 
treatment options. Therefore, the development of novel chemothera-
peutic modalities based on a deeper understanding of the disease is 
essential for improving patient survival. We have recently developed 
Minnelide, a novel prodrug of the diterpene triepoxide, triptolide, as 
a novel chemotherapy against pancreatic cancer. Although Minnelide 
has shown great promise in preclinical studies using various animal 
models of pancreatic cancer, its mechanism of action remains unclear. 
NFkB activity and HSP70 expression are pro-survival pathways up-
regulated in pancreatic cancer. Previous studies from our group and 
others have shown that triptolide decreases NFkB activity. We have 
also shown that triptolide-mediated loss of HSP70 results in pancre-
atic cancer cell death. However, it is unclear if down-regulation of 
both HSP70 and NFkB are part of sequential or parallel pathways. 
We hypothesized that a triptolide-mediated decrease in NFkB activity 
results in down-regulation of HSPs, resulting in cell death.
Patients (or Materials) and Methods: Tumor volume evaluation: 
5 × 105 MIA PaCa-2, S2-VP10, S2-013, AsPC-1, or KPC (derived 
from KRasG12D; Tp53R172H; Pdx-1 Cre animals) pancreatic can-
cer cells were injected subcutaneously into animals and tumor volume 
measured 28 days postinoculation. RNA and Protein: RNA levels 
were assessed using real-time qPCR. Protein levels were evaluated by 
western blotting. NFkB activity: NFkB activity was measured using 
a p50 binding assay kit (Pierce).
Results: Using either KPC cell lines, known to mimic human pan-
creatic cancer progression, or human tumors, we show that the KPC 
cell line is the most aggressive of all cell lines tested in its ability to 
form tumors. The KPC cell line also possesses the highest NFkB activ-
ity of all cell lines tested, accentuating the importance of NFkB in 
pancreatic cancer. To evaluate the mechanism of action of Minnelide, 
we used 2 human tumor-derived pancreatic cancer cell lines: MIA 
PaCa-2, derived from a primary tumor, and S2-VP10, derived from 
a liver metastasis. In both of these cell lines, triptolide treatment 
decreases RNA and protein levels of p50 and p65, as well as NFkB 
Table. FBF ratio (% increase from baseline)
ACH 0.05 ACH 2.0 ACH 8.0 SNP 0.06 SNP 0.2 SNP 0.6
Before 
sunitinib
246 (100) 1098 
(765)
1412 
(737)
692 (357) 1184 
(552)
3703 
(2320)
After 
sunitinib
201 (76) 252 (72) 542 (144) 378 (158) 1078 
(614)
1746 
(665)
